Abstract Details

<< Back to Detailed Agenda

8/23/2022  |   10:45 AM - 11:10 AM   |  Governor General II

Standards of care for cytomegalovirus and congenital cytomegalovirus: a qualitative assessment of st

Globally, cytomegalovirus (CMV) seroprevalence is 83% in the general population and 86% in women of reproductive age. Despite this, many women are unaware of the risk of congenital CMV infection during pregnancy, and most professional guidelines oppose routine screening due to the lack of appropriate treatment. To better understand the disparity between CMV standards of care (SoC) and public health needs, a series of semi-structured qualitative interviews with international CMV stakeholders were completed. Key themes and trends were analyzed to highlight perspectives on CMV SoC and environmental needs to drive improvement and reduce disease burden. Initial results indicate that stakeholders differ in opinions on SoC and best practices, but there was alignment that increased data and familiarity with CMV could shift current SoC practices. It was evident that there is a need for patient centricity and improved dialogue to reduce risk of vertical infection. There were clear differences in care between the United States and Canada, which caused variations in guidelines across countries. Moving forward, biotech companies can support optimization of CMV SoC by contributing to evidence generation and healthcare practitioner education.

  • Evaluate stakeholder perceptions on CMV standard of care guidelines
  • Assess how these guidelines are communicated, how they inform clinical practice, and factors that hinder uptake by providers
  • Identify factors that drive change in clinical practice guidelines for CMV screening and prevention

Presentation:
This presentation has not yet been uploaded.

Handouts:
No handouts have been uploaded.

Session Evaluation


Stephanie Kalb (POC-Point of Contact,Primary Presenter), Stephanie.kalb@modernatx.com;
Stephanie Kalb, PhD, is an Associate Medical Director on Moderna’s Medical Affairs Team, which is focused on vaccines to address CMV and other latent viruses. She received her PhD from Boston University School of Medicine.

      ASHA DISCLOSURE:

Financial - Receives Salary, Ownership interest (e.g., stocks, stock options or other ownership interest excluding diversified mutual funds) for Employment from Moderna, Inc..  

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - Receives support from Moderna, Inc. for Employee of Moderna, Inc. and holds stock/stock options in the company.